SEC Form 4 · accession 0001192482-18-000386
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Armando Anido
Officer — Chairman & Chief Exec. Officer · Director
Period of report
Aug 6, 2018
Accepted (ET)
Aug 7, 2018 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 6, 2018 | P | 15,000 | $5.9615 | A | 352,512 | D | |
| Common StockF2 | holding | — | — | — | 26,595 | I | See footnote | |
| Common StockF2 | holding | — | — | — | 13,297 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.78 to $6.07, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
- F2TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to the shares held by the trusts.